Comprehensive Assessment of Serum Estradiol Impact on Selected Physiologic Markers Observed During in-Vitro Fertilization and Embryo Transfer Cycles

Grace Wing Shan Kong1, Lai Ping Cheung1, Christopher John Haines2, and Po Mui Lam1
1 Department of Obstetrics and Gynecology, Prince of Wales Hospital, Shatin, Hong Kong SAR
2 Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong SAR

Abstract

Objective: This investigation assessed the effect of serum estradiol levels on outcomes of in-vitro fertilization and embryo transfer (IVF) cycles.

Materials and Method: This was a retrospective cohort study of 1123 IVF cycles comparing impact of estradiol (E2) levels on follicular development, fertilization, embryo quality, implantation, pregnancy rate, miscarriage rate, and selected obstetric complications.

Results: We found high serum E2 levels to be significantly associated with increased number of mature follicles and mature oocytes retrieved (p<0.01, for both). E2 levels were also associated with more viable and good-quality embryos (p<0.01). There was no significant impact of E2 on oocyte maturation, fertilization rate, embryo quality, or overall pregnancy rates. Moreover, high E2 levels were significantly associated with higher implantation rates and reduced incidence of miscarriage (p<0.05, for both).

Conclusion: Within the safety range in clinical practice, our data demonstrate a generally positive effect of high serum E2 on selected IVF parameters.

Keywords
Estradiol; in-vitro fertilization; embryo transfer

Introduction

In the clinical practice of in-vitro fertilization and embryo transfer (IVF), controlled ovarian hyperstimulation (COH) is a common technique to maximize the number of mature oocytes retrieved. This approach must be balanced with the recognized risks of ovarian hyperstimulation syndrome (OHSS), which can result if follicular recruitment is too robust. Together with the multifollicular development, COH is inevitably associated with a supra-physiological serum level of E2 which in turn may affect endometrial receptivity [1]. The elevated serum E2 estradiol levels during COH may therefore be associated either with an increased chance of pregnancy (reflecting a better ovarian response), or an impaired reproductive outcome secondary to altered endometrial receptivity.

Possible associations between serum E2 levels and IVF outcomes have been the focus of research interest for many years. Several studies have illustrated the detrimental effect of high serum E2 levels on IVF outcome [2,3] although this finding has not been confirmed in others [4–8]. Indeed, some investigators have noted that serum E2 can positively predict IVF outcomes via the retrieval of a greater number of oocytes [9–11]. Conflicting results of previous publications might be related to differences in
outcome measures as well as threshold values used to define “high” E2 levels. While most investigators have focused on the implantation and pregnancy rates which are only the final steps, an IVF cycle indeed involves a sequence of highly synchronized events each of which must proceed optimally. Not only endometrial receptivity and embryo implantation, but also follicular development, fertilization, and embryo quality are all important keys for determining success of an IVF cycle.

This study aims to present a comprehensive assessment of the impact of serum E2 on the different components of an IVF cycle. We compare the impact of estradiol levels measured on the day of ovulatory dose of human chorionic gonadotrophin (hCG) on follicular development, fertilization, embryo quality, implantation, pregnancy rate, miscarriage rate, and complications such as OHSS.

**Methods**

This retrospective cohort study encompassed 1123 IVF cycles performed during January 2005 to December 2007 at the Assisted Reproductive Unit (Hong Kong). This is the tertiary referral centre affiliated with the Department of Obstetrics and Gynecology, The Chinese University of Hong Kong. Since there was no human subjects tested or interviewed specifically for the purpose of this investigation, it was determined that IRB approval was not required for our retrospective study. All IVF cycles performed during the above period were analyzed; no cases were excluded. The causes of infertility for women undergoing IVF cycles included tubal, male, endometriosis, unexplained and mixed factors. Intracytoplasmic sperm injection (ICSI) was carried out in couples with severe semen abnormalities.

**Controlled Ovarian Hyperstimulation (COH) Protocol**

All subjects received a standard protocol for ovulation induction. Pituitary suppression was achieved via long (luteal) gonadotropin releasing hormone agonist (GnRHa) down-regulation protocol. Buserelin nasal spray (Suprecur, Hoechst, Germany) 600 mcg daily was administered for at least 14d from the mid-luteal phase of the preceding cycle. Complete pituitary desensitization was confirmed by low serum luteinizing hormone (LH < 10 IU/L) and estradiol (E2 < 200 pmol/L) concentrations. Patients also had an ultrasound examination to exclude functional ovarian cysts and verify that endometrial thickness was <5mm. Once adequate downregulation was confirmed, ovarian stimulation commenced with human menopausal gonadotropins (hMG) (Pergonal, Serono, Aubonne/Switzerland) or recombinant follicle stimulating hormone (rFSH) (Gonad-F, Serono, Aubonne/Switzerland; or Puregon, Organon, Oss, Holland). For patients undergoing their first IVF cycles, initial doses of hMG (or equivalent dose of rFSH) were 225, 300, or 375 IU/d for female age groups of < 33yrs, 33–35yrs, and >35yrs, respectively. The starting dose was reduced to 150IU/d for anticipated high responders (i.e., PCO patients). Alternatively, baseline gonadotropin dose was increased to 450IU/d for anticipated poor responders, such as those with elevated basal serum FSH levels. For patients undergoing subsequent IVF cycles, the starting doses were influenced by ovarian response in the prior cycle/s as well as patient age. Neither antral follicle count nor ovarian volume was considered in dose determination.

Ovarian response was monitored by transvaginal ultrasound and serum E2 concentrations from stimulation day 6 onwards. The dose of gonadotropins was adjusted during the stimulation depending on the ovarian response. When follicular recruitment was considered adequate (defined by the presence of at least three mature follicles 18mm in diameter), an ovulatory dose of hCG (Profasi, Serono, Aubonne/Switzerland) 5,000 IU was given and transvaginal oocyte retrieval was performed approximately 36h later. All patients received a titrated dose of diazepam and pethidine for analgesia. For patients with poor ovarian response (defined as less than three mature follicles on ultrasound), the cycle was cancelled and retrieval was not attempted. Embryo transfer was performed three days after oocyte retrieval and surplus embryos were cryopreserved. Patients undergoing embryo transfer received intramuscular hCG or vaginal progesterone for luteal phase support beginning on the day of oocyte retrieval. For those with excessive ovarian response (defined as >20 oocytes retrieved, or 15–20 oocytes retrieved but with risk factors for OHSS such as known PCO or past history of OHSS), all viable embryos were cryopreserved instead so as to minimize the risk of OHSS.

**Outcome Measures**

IVF cycle outcome was assessed by urine pregnancy test performed 10d after the final dose of hCG (luteal phase support) or two weeks after embryo transfer, whichever occurred later. If a positive test was reported, vaginal ultrasound of the pelvis would be performed two weeks later to assess the site, the number, and the viability of gestation. Pregnancy rate was defined as positive urine pregnancy test per embryo transfer, while implantation rate was defined as number of gestational sacs per embryo transferred. The pregnancy outcomes, such as miscarriage and live birth were also recorded, along with multiple gestation rate and complications.
Clotted blood samples (5ml) were collected by peripheral
venipuncture at the conclusion of follicular recruitment
(on the day of ovulatory dose of hCG) for serum E$_2$
measurements. Serum estradiol levels were quantified by using
a competitive immunoassay with direct chemiluminescent
technology (Bayer, Tarrytown, NY, USA). Interassay
coefficients of variation of the assay were 9.8%, 4.2%, and
8.7% at concentrations of 250, 859, and 2830 pmol/L,
respectively.

Data on patient characteristics, ovarian stimulation proto-
col and embryo quality were also collected. These included
ages of patients, type, duration, and cause of infertility,
ovarian reserve assessment (CD#3 serum FSH levels),
number of previous IVF cycles, duration and total dose of
gonadotropin treatment, endometrial thickness on day of
ovulatory hCG, number of ovarian follicles > 15 mm in
diameter, number of mature oocytes and total oocytes
retrieved, fertilization rate, and number of viable embryos
and good-quality embryos (which were defined as four-
cell or more cleaved embryos, seven-cell or more cleaved
embryos and blastocysts transferred 48h, 72h and 120h
after retrieval, respectively). The number of embryos
transferred per patient was also reviewed.

Statistics
Statistical analysis was carried out using SPSS (version
16). Continuous data were expressed as mean ± standard
deviation (SD). One-way analysis of variance (ANOVA)
with Bonferroni correction for multiple comparisons was
used to analyze continuous data and chi-square test was
used to analyze categorical data, where appropriate.
P<0.05 was considered statistically significant.

Results
A total of 1123 IVF cycles were studied. Among them,
418 (37.2%) cycles had ICSI performed for severe semen
abnormalities; 607 (54.1%) cycles were the first IVF trial
for the women. The women aged 35.8 ± 3.7 years and the
baseline serum FSH level was 7.7 ± 2.7 mmol/L. Con-
cerning the outcomes, the mean (±SD) number of total
oocytes and mature oocytes retrieved per cycle were 9.8
± 5.6 and 7.8 ± 4.6, respectively. Mean (±SD) number of
viable embryos and good embryos per cycle were 2.7 ±
2.2 and 2.0 ± 2.1, respectively. The overall implantation
rate was 22.6% while the overall pregnancy rates per cycle
initiated, per cycle with oocyte retrieval, and per cycle
with embryo transfer were 31%, 31% and 36%, respec-
tively.

The mean, 25 percentile, median and 75 percentile of
serum E$_2$ levels on day of hCG administration were
13,200, 6000, 10500 and 17300 pmol/l, respectively.
Based on these percentiles, the IVF cycles were catego-
rized into four groups: Group 1 (243 cycles with E$_2$ < 6000
pmol/L), Group 2 (393 cycles with E$_2$ = 6000–12000
pmol/L), Group 3 (231 cycles with E$_2$ = 12000–18000
pmol/L), and Group 4 (256 cycles with E$_2$ > 18000 pmol/
L). In Group 4 (the high responder group), 54 cycles (20%)
underwent elective cryopreservation of all embryos in
view of anticipated high risk of OHSS. Among them, 18
(33%) cycles did develop OHSS. The incidence of OHSS
for the whole cohort was 12.5% (140 cycles), and 1.2%
(13 cycles) were severe cases.

Women in Group 4 were younger (34.7 ± 3.5 vs. 37.0 ±
3.8 & 35.8 ± 3.6yrs, p<0.01), had lower average baseline
FSH level (6.7 ± 1.6 vs. 8.7 ± 2.9 & 7.9 ± 2.6 IU/L, p<0.01)
and consumed a lower gonadotropin dose during IVF
(3021.4 vs. 4352.9 & 3824.4 IU, p<0.01) compared to
patients in Group 1 and 2, respectively. However, there
were no significant differences among the groups in other
potential covariates, including frequency of PCO diagno-
sis, number of previous IVF cycles, fertilization method,
and cancellation rate due to poor ovarian response (see
Table 1).

Follicular development in Group 4 demonstrated an
increased number of follicles >15mm in diameter (12.4 ±
3.7 vs. 4.4 ± 1.9, 6.9 ± 2.6 & 9.3 ± 3.2, p<0.01), more
oocytes retrieved (15.3 ± 6.1 vs. 5.3 ± 3.0, 8.3 ± 3.6 & 10.9
± 4.5, p<0.01), and a higher average number of mature
oocytes retrieved (12.2 ± 5.1 vs. 4.3 ± 2.6, 6.6 ± 3.0 & 8.7
± 3.8, p<0.01) compared to s 1, 2 and 3, respectively.
However, there were no significant differences among
study groups regarding oocyte maturation rate or average
number of cycles where poor oocyte quality was observed
(see Table 2).

The fertilization rate was 60%, which was not signifi-
cantly different among these 4 groups with different E$_2$
levels. However, IVF cycles in Group 4 had a higher mean
number of viable embryos (3.9 ± 3.1 vs. 1.7 ± 1.5 & 2.5 ±
1.7, p<0.01), a higher average number of good embryos
(2.9 ± 2.8 vs. 1.2 ± 1.4 & 1.8 ± 1.7, p<0.01), but a reduced
proportion of viable embryos per fertilized oocyte (0.49 ±
0.27 vs. 0.58 ± 0.36 & 0.58 ± 0.30, p<0.01) compared
Group 1 and 2, respectively. However, there were no sig-
nificant differences in proportion of good embryos per
fertilized oocyte among the study groups (see Table 2).

There were no significant differences in pregnancy rates,
live birth rates per cycle, or miscarriage and multiple ges-
tation rates per pregnancy among the four groups. How-
ever, IVF cycles in Group 4 demonstrated a higher implan-
tation rate (0.28 ± 0.38 vs. 0.20 ± 0.33, p=0.04) compared
Also, Group 4 was associated with lower miscarriage rate (12.2 vs. 23.6% & 24.2%, \( p < 0.05 \)) compared to Groups 1 and 2, respectively. As expected, the complication rate of OHSS was significantly higher in Group 4 (22 vs. 4.5% & 9.7%, \( p < 0.01 \)) compared to Groups 1 and 2, respectively (see Table 3).

For the sub-set of patients with extremely high E2 levels accompanied by elective embryo cryopreservation (no fresh transfer), these cycles were associated with more follicles, more total oocytes retrieved, more mature oocytes retrieved and more viable embryos. However, oocyte maturation, number of cycles with poor oocyte quality, fertilization rate, proportion of viable embryos per fertilized oocyte, number of good quality embryos, and proportion of good embryos per fertilized oocyte were not significantly different from the other 4 groups.

A subgroup analysis was also performed for patients with a favorable prognosis, (i.e., those age <38yrs and with CD#3 FSH level <10mmol/L). A total of 664 IVF cycles met this criteria and were eligible for analysis; these were stratified into four categories according to the same E2 threshold levels as used in the overall analysis. Tables 4 and 5 summarize IVF outcomes in this subgroup of favorable prognosis patients. The results were similar to

---

### Table 1:

Patient characteristics observed among four groups of in-vitro fertilization cycles as a function of serum estradiol.

| Characteristics       | Group 1 (n=243) | Group 2 (n=393) | Group 3 (n=231) | Group 4 (n=256) |
|-----------------------|-----------------|-----------------|-----------------|-----------------|
| Age (yrs)             | 37.0 ± 3.8      | 35.8 ± 3.6      | 35.5 ± 3.5      | 34.7 ± 3.5      |
| Day 3 FSH (IU/L)      | 8.7 ± 2.9       | 7.9 ± 2.6       | 7.1 ± 1.9       | 6.7 ± 1.6       |
| PCO                   | 4 (1.6%)        | 22 (5.6%)       | 11 (4.8%)       | 16 (6.3%)       |
| First trial of IVF    | 122 (50.2%)     | 211 (53.7%)     | 115 (49.8%)     | 159 (62.1%)     |
| Fertilization with ICSI| 89 (36.6%)     | 152 (38.7%)     | 84 (36.4%)      | 93 (37.2%)      |
| Total dose of gonadotropin (IU) | 4355# | 3824# | 3512# | 3021# |
| Cancellation of cycle | 3 (1.2%)        | 1 (0.3%)        | 1 (0.4%)        | 1 (0.4%)        |

Values are numbers (percentages) of cycles or mean ± standard deviation.

n = number of cycles of in-vitro fertilization

FSH: Follicle stimulation hormone

PCOS: Polycystic ovary syndrome

IVF: In vitro fertilization

ICSI: Intracytoplasmic sperm injection

* \( (p<0.05) \) and

# \( (p<0.01) \) indicate significant differences vs. Group 4

### Table 2:

Follicular development, fertilization and embryo quality in various groups of in vitro fertilization cycles with different serum estradiol levels

| Outcome                           | Group 1 (n=243) | Group 2 (n=393) | Group 3 (n=231) | Group 4 (n=256) |
|-----------------------------------|-----------------|-----------------|-----------------|-----------------|
| Number of follicles >15mm         | 4.4 ± 1.9#      | 6.9 ± 2.6#      | 9.3 ± 3.2#      | 12.4 ± 3.7      |
| Number of total oocytes retrieved | 5.3 ± 3.0#      | 8.3 ± 3.6#      | 10.9 ± 4.5#     | 15.3 ± 6.1      |
| Number of mature oocytes retrieved| 4.3 ± 2.6#      | 6.6 ± 3.0#      | 8.7 ± 3.8#      | 12.2 ± 5.1      |
| Maturation rate per oocyte retrieved| 0.81 ± 0.19    | 0.80 ± 0.18     | 0.80 ± 0.14     | 0.80 ± 0.15     |
| Cycles with poor oocyte quality   | 118(48.6%)      | 186(47.3%)      | 110(47.6%)      | 104(40.6%)      |
| Fertilization rate                | 0.61 ± 0.32     | 0.62 ± 0.27     | 0.59 ± 0.26     | 0.61 ± 0.25     |
| Number of total viable embryos    | 1.7 ± 1.5#      | 2.5 ± 1.7#      | 2.8 ± 1.9#      | 3.9 ± 3.1       |
| Viable embryo per fertilized oocyte| 0.58 ± 0.36#   | 0.58 ± 0.30#    | 0.52 ± 0.29     | 0.49 ± 0.27     |
| Number of good quality embryos    | 1.2 ± 1.4#      | 1.8 ± 1.7#      | 2.0 ± 1.8#      | 2.9 ± 2.8       |
| Good quality embryos per fertilized oocyte | 0.39 ± 0.36 | 0.38 ± 0.31 | 0.35 ± 0.29 | 0.36 ± 0.28 |

Values are numbers (percentages) of cycles, or mean ± standard deviation.

n = number of cycles of in vitro fertilization

# \( (p<0.01) \) indicates significant differences from Group 4

---

J Exp Clin Assist Reprod 2009;6:5 Kong, et al.
the overall group, but with significant improvement in follicular development and number of embryos. There was also a reduced rate of miscarriage (but an increased risk of OHSS) in Group 4 compared to Groups 1 and 2. However, there were no significant differences among groups in fertilization rate, implantation rate, pregnancy and live birth rates per cycle, or miscarriage and multiple gestation rates.

### Discussion

It is well established that E2 is essential in an IVF cycle by protecting developing follicles from atresia and stimulating endometrial growth for subsequent implantation and further pregnancy. However, the associations between various serum E2 levels and particular IVF outcomes have remained controversial. Low serum estradiol level is appa-

| Outcome | Group 1 (n=243) | Group 2 (n=393) | Group 3 (n=231) | Group 4 (n=256) | EC (n=54) |
|---------|-----------------|-----------------|-----------------|-----------------|----------|
| Implantation rate | 0.23 ± 0.35 | 0.20 ± 0.33 | 0.21 ± 0.35 | 0.28 ± 0.38 | -- |
| Pregnancy per initiated cycle | 72/243 (29.6%) | 120/393 (30.5%) | 71/231 (30.7%) | 82/256 (32.0%) | -- |
| Pregnancy per OR | 72/240 (30.0%) | 120/387 (31.0%) | 71/209 (34.0%) | 82/186 (44.1%) | -- |
| Live birth per ET | 53/196 (27.0%) | 83/357 (23.2%) | 59/209 (27.3%) | 68/186 (36.6%) | -- |
| Miscarriage per pregnancy | 17/72 (23.6%) | 29/120 (24.2%) | 7/71 (9.9%) | 10/82 (12.2%) | -- |
| Multiple gestation rate per pregnancy | 16/72 (22.2%) | 25/120 (20.8%) | 19/71 (26.8%) | 31/82 (37.8%) | -- |
| OHSS | 11/243 (4.5%) | 38/393 (9.7%) | 35/231 (15%) | 56/256 (22%) | 18/54 (33%) |

Values are numbers (percentages) of cycles or mean ± standard deviation.

n = number of cycles of in-vitro fertilization

EC: Elective cryopreservation of all embryos

OR: Oocyte retrieval

ET: Embryo transfer

OHSS: Ovarian hyperstimulation syndrome

*p<0.05 and

#p<0.01 indicate significant differences vs. Group 4

| Outcome | Group 1 (n = 97) | Group 2 (n = 226) | Group 3 (n = 146) | Group 4 (n = 195) | EC (n=46) |
|---------|-----------------|-----------------|-----------------|-----------------|----------|
| Number of follicles > 15mm | 5.0 ± 2.3 | 7.2 ± 2.7 | 9.4 ± 3.1 | 12.4 ± 3.7 | 15.3 ± 4.2 |
| Number of total oocytes retrieved | 6.0 ± 3.3 | 8.4 ± 3.7 | 11.0 ± 4.6 | 15.3 ± 6.0 | 21.6 ± 6.1 |
| Number of mature oocytes retrieved | 5.0 ± 2.9 | 6.6 ± 3.0 | 8.9 ± 3.9 | 12.3 ± 5.0 | 17.1 ± 5.4 |
| Maturation per oocyte retrieved | 0.82 ± 0.17 | 0.79 ± 0.18 | 0.81 ± 0.14 | 0.81 ± 0.14 | 0.79±0.11 |
| Cycles with poor oocyte quality | 46 (47.4%) | 96 (42.5%) | 64 (34.3%) | 79 (40.5%) | 15(32.6%) |
| Fertilization rate | 0.65 ± 0.29 | 0.61 ± 0.28 | 0.59 ± 0.27 | 0.61 ± 0.25 | 0.61±0.22 |
| Number of total viable embryos | 2.1 ± 1.8 | 2.4 ± 1.7 | 2.8 ± 2.0 | 3.9 ± 3.1 | 6.4 ± 4.3 |
| Viable embryo per fertilized oocyte | 0.56 ± 0.33 | 0.57±0.30 | 0.52 ± 0.29 | 0.48 ± 0.26 | 0.59±0.29 |
| Number of good quality embryos | 1.7 ± 1.7 | 1.8 ± 1.7 | 2.1 ± 1.9 | 3.0 ± 2.9 | 4.5 ± 4.0 |
| Good quality embryos per fertilized oocyte | 0.44 ± 0.35 | 0.39 ± 0.32 | 0.37 ± 0.30 | 0.36 ± 0.28 | 0.40±0.31 |

Values are numbers (percentages) of cycles, or mean ± standard deviation.

n = number of cycles of in-vitro fertilization

EC: Elective cryopreservation of all embryos

#p<0.01 indicates significant difference vs. Group 4
Table 5: Implantation rate, pregnancy and live birth rates per cycle (including miscarriage and multiple gestation rates) observed in favorable prognosis IVF patients as a function of serum estradiol level.

| Outcome                  | Group 1 (n = 97) | Group 2 (n = 226) | Group 3 (n = 146) | Group 4 (n = 195) |
|--------------------------|------------------|-------------------|-------------------|-------------------|
| Implantation rate        | 0.30 ± 0.38      | 0.24 ± 0.36       | 0.26 ± 0.37       | 0.34 ± 0.39       |
| Pregnancy per initiated  | 80/203 (39.4%)   | 50/146 (34.2%)    | 60/195 (35.4%)    | 60/195 (35.4%)    |
| Pregnancy per OR cycle   | 39/97 (40.2%)    | 50/145 (34.5%)    | 60/195 (35.4%)    | 60/195 (35.4%)    |
| Pregnancy per ET cycle   | 39/97 (40.2%)    | 50/145 (34.5%)    | 60/195 (35.4%)    | 60/195 (35.4%)    |
| Live birth per ET cycle  | 27/81 (33.3%)    | 40/130 (30.8%)    | 58/137 (42.3%)    | 58/137 (42.3%)    |
| Miscarriage per pregnancy| 18/80 (22.5%)    | 4/50 (8%)         | 8/69 (11.6%)      | 8/69 (11.6%)      |
| Multiple gestation per pregnancy | 8/39 (20.5%) | 18/80 (22.5%) | 4/50 (8%) | 8/69 (11.6%) |
| OHSS                     | 7/97 (7.4%)      | 26/226 (11.5%)    | 3/146 (15.9%)     | 43/195 (21.9%)    |

Values are numbers (percentages) of cycles, or mean ± standard deviation.

OR: Oocyte retrieval
ET: Embryo transfer
OHSS: Ovarian hyperstimulation syndrome

* (p<0.05) indicates significant difference vs. Group 4

Currently associated with poor IVF outcomes. However, the possible adverse impact of elevated serum E2 level on the IVF outcomes is still under debate. A meta-analysis published in 2004 regarding the associations between serum estradiol level on day of hCG administration and pregnancy after IVF drew no conclusions [12]. The current available evidence, though reasonably extensive, does bring some limitations with the difference in the cut-off values for E2 level being the obvious concern.

Earlier work has shown that high serum E2 levels in the setting of IVF might indicate increased ovarian response [9–11], increased risk of OHSS [11] and/or reduced endometrial receptivity [2,3]. Indeed, serum E2 level measured on day of ovulatory dose of hCG is a common clinical indicator for elective cryopreservation of all viable embryos as a prophylactic measure to reduce risk of OHSS, although different assisted reproductive centres have developed different E2 threshold levels for this. Studies with lower cut-off for serum E2 level above which all embryos were cryopreserved could demonstrate the impact of E2 level on ovarian response only, but not its impact on OHSS development or endometrial receptivity. However, it would be unethical to place patients at risk of developing severe OHSS by allowing fresh embryo transfer in cycles with an extremely high serum E2 level to reveal the impact on endometrial receptivity. The incidence of severe OHSS in our unit during the study period was 1.2%. Within this safety range in clinical practice, our retrospective study has evaluated the impact of serum E2 levels on day of hCG administration on the outcomes from IVF in a comprehensive manner.

The relatively higher serum E2 levels measured from controlled ovarian hyperstimulation reflected a better ovarian response of IVF, and as expected, these cycles were from patients with better ovarian reserve as suggested by their younger ages and lower baseline FSH levels. Most importantly, our study has observed a negative relationship between the consumption of gonadotropin and serum E2 levels at the time of hCG administration. This finding suggests that a high E2 level is not necessarily a result of high-dose gonadotrophin stimulation. Indeed, for women with good ovarian reserve, the lower dose of gonadotrophin is enough to trigger an adequate ovarian response with high serum E2 levels. Therefore, the dosage of gonadotrophin used in controlled ovarian hyperstimulation should be adjusted, especially for women with good prognostic factors so as to avoid further increase in serum estradiol level which may result in potential detrimental effect on the IVF cycle and OHSS.

Although the incidence of severe OHSS (1.2%) in our unit during the study period was acceptable, the incidence of overall OHSS was too high. After this retrospective analysis, we reevaluated our practice and implemented some changes to reduce the risk of OHSS. Specifically, we have modified the starting doses of gonadotropin to be calibrated not only by patient age and previous treatment response, but also by antral follicle count. This has resulted in starting doses of gonadotropins now being lower for most patients. Coasting in selected cycles with high risk of OHSS will also be considered, all IVF patients will have vaginal progesterone (rather than intramuscular hCG) for luteal phase support.

In agreement with previous studies which showed the relationship between high serum E2 level and good ovarian response [9–11], our data demonstrate the improvement of follicular development as well as the quality and
quantity of oocyte retrieval in term of number and maturity of oocytes retrieved. We specifically investigated the relationship between the proportion of mature oocyte per oocyte retrieved and the serum E$_2$ levels, and found that there were no significant associations between them. This observation suggests that the higher E$_2$ levels only result in more oocytes (and so an increased number of mature oocytes proportionally), but does not promote the maturation of oocytes per se. Concerning 2pm fertilization, our study did not observe any significant differences in fertilization rates among the four groups with different levels of serum E$_2$. Thus, our findings showed high serum E$_2$ were associated with a better ovarian response but had no effect on fertilization rate itself.

Although some studies have commented on the increased embryo yield in patients with high serum E$_2$ levels [3,9], ours is the first description of the impact of serum E$_2$ levels on embryo quality. In this investigation, we found that high serum E$_2$ levels were associated with increased number of viable embryos and good-quality embryos per cycle. However, the proportion of viable embryos per fertilized embryo was indeed lower in the group with high E$_2$ levels. These observations suggest that high E$_2$ levels are associated with more oocytes retrieved and so more viable or good-quality embryos proportionally, but they are not associated with improvement in the quality of embryo. Therefore, we do not anticipate any impact of these high serum E$_2$ levels on the outcome of the subsequent cryopreserved embryo cycles. However, this question remains to be answered in further analysis.

The impact of high E$_2$ level (measured on day of hCG administration) on implantation is controversial. Some authors have reported that high E$_2$ level could be associated with no change or even an increased implantation rate [9,11,13,14], while others reported a detrimental effect and impaired implantation [1,2,15,16]. Arslan et al analyzed the cumulative E$_2$ effect (using the “area under the curve” approach) which maybe a better reflection of the total E$_2$ exposure of both oocytes and endometrium [17]. In parallel with our work, they found that different levels of E$_2$ exposure did not likely affect oocyte and embryo quality [17]. However, they demonstrated detrimental effects of high cumulative E$_2$ exposure on embryo implantation [17]. Postulated mechanisms for reduced implantation include impaired endometrial receptivity [17,18], altered E$_2$ to progesterone ratio [19], and reduction in the nuclear receptor for E$_2$ and progesterone in endometrial stroma and glands [20]. Morphological and biochemical changes in secretory endometrium have also been demonstrated [21–24]. Within the safety range for OHSS in our clinical practice, we indeed demonstrated a positive effect of high serum E$_2$ levels on IVF outcome in terms of a higher implantation rate and a lower miscarriage rate, which is a reflection of endometrial receptivity.

In conclusion, we have found that a high serum E$_2$ level at the time of hCG administration is a marker of a robust ovarian response to controlled ovarian hyperstimulation and is accompanied by more mature follicles, more mature oocytes retrieved, and a higher yield of viable and good-quality embryos. There is no significant impact of serum E$_2$ level on fertilization rate, maturation of oocytes and quality of embryo per se, or the overall pregnancy rates. The high E$_2$ level did not adversely affect the endometrial receptivity but indeed is associated with a higher implantation rate and a lower miscarriage rate.

References

1. Pellicer A, Valbuena D, Cano F, Renohú J, Simón C. Lower Implantation Rates in High Responders: Evidence for an Altered Endocrine Milieu During the Preimplantation Period. Fertil Steril 1996;65(6):1190–1195.
2. Simón C, Cano F, Valbuena D, Renohú J, Pellicer A. Clinical Evidence for a Detrimental Effect on Uterine Receptivity of High Serum Oestradiol Concentrations in High and Normal Responder Patients. Hum Reprod 1995;10(9):2432–2437.
3. Ng EHY, Yeung WS, Lau EY, So WW, Ho PC. High Serum Oestradiol Concentrations in Fresh IVF Cycles Do Not Impair Implantation and Pregnancy Rates in Subsequent Frozen- thawed Embryo Transfer Cycles. Hum Reprod 2000;15(2):250–255.
4. Mettler L, Tavergen JN. Significance of Oestradiol Values in IVF-ET Under a Combined GnRH Analogue–Desensitization and Simultaneous Gonadotrophin Stimulation for the Outcome of Pregnancies. Hum Reprod 1989;4(8 Suppl):59–64.
5. Sharara FI, McClamrock HD. High Estradiol Levels and High Oocyte Yield Are Not Detrimental to In Vitro Fertilization Outcome. Fertil Steril 1999;72(3):401–405.
6. Dor J, Seidman DS, Ben-Shlomo I, Levran D, Karasik A, Mashiach S. The Prognostic Importance of the Number of Oocytes Retrieved and Estradiol Levels in Poor and Normal Responders in in-Vitro Fertilization (IVF) Treatment. J Assist Reprod Genet 1992;9(3):228–232.
7. Papageorgiou T, Guibert J, Goffinet F, Patrat C, Fulla Y, Janssens Y, Zorn JR. Percentile Curves of Serum Estradiol Levels During Controlled Ovarian Stimulation in 905 Cycles Stimulated with Recombinant FSH Show That High Estradiol Is Not Detrimental to IVF Outcome. Hum Reprod 2002;17(11):2846–2850.
8. Chen CH, Zhang X, Barnes R, Confino E, Milad M, Puscheck E, Kazer RR. Relationship Between Peak Serum Estradiol Levels and Treatment Outcome in in-Vitro Fertilization Cycles After Embryo Transfer on Day 3 or Day 5. Fertil Steril 2003;80(1):75–79.
9. Chenette PE, Sauer MV, Paulson RJ. Very High Serum Estradiol Levels Are Not Detrimental to Clinical Outcome of in Vitro Fertilization. Fertil Steril 1990;54(5):858–863.
10. Gelety TJ, Buyalos RP. The Influence of Supraphysiologic Estradiol Levels on Human Nidation. J Assist Reprod Genet 1995;12(7):406–412.
11. Blazar AS, Hogan JW, Frankfurter D, Hackett R, Keeve DL. Serum Estradiol Positively Predicts Outcomes in Patients Undergoing In Vitro Fertilization. Fertil Steril 2004;81(6):1707–1709.
12. Kosmas IP, Kolibianakis EM, Devroey P. Association of Estradiol Levels on the Day of hCG Administration and Pregnancy Achievement in IVF: a Systematic Review. *Hum Reprod* 2004;19(11):2446–2453.

13. Testart J, Belaisch-Allart J, Forman R, Gazengel A, Strubb N, Hazout A, Frydman R. Influence of Different Stimulation Treatments on Oocyte Characteristics and In-Vitro Fertilizing Ability. *Hum Reprod* 1989;4(2):192–197.

14. Toner JP, Brzyski RG, Oehninger S, Veeck LL, Simonetti S, Muasher SJ. Combined Impact of the Number of Pre-Ovulatory Oocytes and Cryopreservation on IVF Outcome. *Hum Reprod* 1991;6(2):284–289.

15. Tarín JJ, Pellicer A. Consequences of High Ovarian Response to Gonadotropins: a Cytogenetic Analysis of Unfertilized Human Oocytes. *Fertil Steril* 1990;54(4):665–670.

16. Pellicer A, Ruiz A, Castellvi RM, Calatayud C, Ruiz M, Tarín JJ, Miró F, Bonilla-Musoles F. Is the Retrieval of High Numbers of Oocytes Desirable in Patients Treated with Gonadotrophin-Releasing Hormone Analogues (GnRHa) and Gonadotrophins? *Hum Reprod* 1989;4(5):536–540.

17. Arslan M, Bocca S, Arslan EO, Duran HE, Stadtmauer L, Oehninger S. Cumulative Exposure to High Estradiol Levels During the Follicular Phase of IVF Cycles Negatively Affects Implantation. *J Assist Reprod Genet* 2007;24(4):111–117.

18. Paulson RJ, Sauer MV, Lobo RA. Embryo Implantation After Human in Vitro Fertilization: Importance of Endometrial Receptivity. *Fertil Steril* 1990;53(5):870–874.

19. Morris JM, Van Wagenen G. Interception: the Use of Postovulatory Estrogens to Prevent Implantation. *Am J Obstet Gynecol* 1973;115(1):101–106.

20. Hadi FH, Chantler E, Anderson E, Nicholson R, McClelland RA, Seif MW. Ovulation Induction and Endometrial Steroid Receptors. *Hum Reprod* 1994;9(12):2405–2010.

21. García JE, Acosta AA, Hsu JG, Jones HW Jr. Advanced Endometrial Maturation After Ovulation Induction with Human Menopausal Gonadotropin/Human Chorionic Gonadotropin for in Vitro Fertilization. *Fertil Steril* 1984;41(1):31–35.

22. Simón C, Mercader A, Frances A, Gimeno MJ, Polan ML, Remohí J, Pellicer A. Hormonal Regulation of Serum and Endometrial IL-1 Alpha, IL-1 Beta and IL-1Ra: IL-1 Endometrial Microenvironment of the Human Embryo at the Apposition Phase Under Physiological and Supraphysiological Steroid Level Conditions. *J Reprod Immunol* 1996;31(3):165–184.

23. Kolb BA, Najmabadi S, Paulson RJ. Ultrastructural Characteristics of the Luteal Phase Endometrium in Patients Undergoing Controlled Ovarian Hyperstimulation. *Fertil Steril* 1997;67(4):625–630.

24. Hadi FH, Chantler E, Anderson E, Nicholson R, McClelland RA, Seif MW. Ovulation Induction and Endometrial Steroid Receptors. *Hum Reprod* 1994;9(12):2405–2410.